Rankings / Longevity — Senolytics & Polyphenols
Senolytics (D+Q combo)
Longevity · Senolytic
Tier C+
Bottom line
Read Off Label grades Senolytics (D+Q combo) as C+ (5.5/10) based on moderate evidence, variable benefit magnitude, and a med-risk safety profile.
First-ever senolytic human trials (Justice 2019, Hickson 2019).
Typical use: D 100 mg + Q 1000 mg x 2-3 consecutive days, then 2-4 weeks off (intermittent "hit-and-run"); multiple cycles — Rx.
What this is
First-ever senolytic human trials (Justice 2019, Hickson 2019). Reduced senescent cell markers in adipose tissue; improved physical function in IPF. Epigenetic clock data mixed. Long-term safety in healthy adults unknown.
Mechanism
Dasatinib (BCR-ABL/Src inhibitor) + Quercetin (flavonoid) selectively kill senescent cells by disabling pro-survival SCAP pathways; cleared SnCs reduce SASP inflammation
Dose & route
D 100 mg + Q 1000 mg x 2-3 consecutive days, then 2-4 weeks off (intermittent "hit-and-run"); multiple cycles
Citations
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6796530/
- https://www.ebiomedicine.com/article/S2352-3964(19)30641-3/fulltext
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10929829/
- https://doi.org/10.3390/cancers18081220
- https://doi.org/10.3389/fonc.2026.1743620
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Senolytics (D+Q combo) work?
- Read Off Label rates the evidence for Senolytics (D+Q combo) as Moderate and the benefit magnitude as variable, producing an overall grade of C+ (5.5/10). First-ever senolytic human trials (Justice 2019, Hickson 2019).
- Is Senolytics (D+Q combo) safe?
- Senolytics (D+Q combo) has a med risk profile in published human data. Legal status: Rx (dasatinib is oncology drug — off-label use). This is not medical advice — see the disclaimer.
- What is the typical dose for Senolytics (D+Q combo)?
- D 100 mg + Q 1000 mg x 2-3 consecutive days, then 2-4 weeks off (intermittent "hit-and-run"); multiple cycles
- How does Senolytics (D+Q combo) work?
- Dasatinib (BCR-ABL/Src inhibitor) + Quercetin (flavonoid) selectively kill senescent cells by disabling pro-survival SCAP pathways; cleared SnCs reduce SASP inflammation
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.